IMMUNOGEN

Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.

Description: IMMUNOGEN This application claims priority from Provisional Application No. 60/234,327, filed September 22, 2000, Provisional Application No. 50/285,173, filed April 23, 2001, from Provisional Application No. , filed September 21, 2001 and from Provisional Application No. , filed September 21, 2002, the entire contents of which are incorporated herein by reference. TECHNICAL FIELD The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen . BACKGROUND As the HIV epidemic continues to spread worldwide, the need for an effective HIV vaccine remains urgent. A key obstacle to HIV vaccine development is the extraordinary variability of HIV and the rapidity and extent of HIV mutation (Wain-Hobson in The Evolutionary biology of Retroviruses, SSB Morse Ed. Raven Press, NY, pgs 185-209 (1994)). Myers, Korber and colleagues have analyzed HIV sequences worldwide and divided HIV isolates into groups or clades, and provided a basis for evaluating the evolutionary relationship of individual HIV isolates to each other (Myers et al (Eds) , Human Retroviruses and AIDS (1995) , Published by Theoretical Biology and Biophysics Group, T-10, Mail Stop K710, Los Alamos National Laboratory, Los Alamos, NM 87545) . The degree of variation in HIV protein regions that contain CTL and T helper epitopes has also recently been analyzed by Korber et al, and sequence variation documented in many CTL and T helper epitopes among HIV isolates (Korber et al (Eds) , HIV Molecular Immunology Database (1995), Published by Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545) . A new level of HIV variation complexity was recently reported by Hahn et al by demonstrating the frequent recombination of HIV among clades (Robinson et al, J. Mol. Evol. 40:245-259 (1995)). These authors suggest that as many as 10% of HIV isolates are mosaics of recombination, suggesting that vaccines based on only one HIV clade will not protect immunized subjects from mosaic HIV isolates (Robinson et al, J. Mol. Evol. 40:245-259 (1995)). The present invention relates to an immunogen suitable for use in an HIV vaccine. The immunogen will induce broadly cross-reactive neutralizing antibodies in humans and neutralize a wide spectrum of HIV primary isolates. SUMMARY OF THE INVENTION The present invention relates to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen . Objects and advantages of the present invention will be clear from the description that follows. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows CCR5 or CXCR4 co-receptor proteins (or their protein or peptide fragments) and soluble CD4 bound to gplβO. Figure 2 shows vesicles or liposomes containing CD4, CCR5 (or CXCR4) bound to gplβO in a vesicle, liposome or an inactivated virion. Figure 3 shows soluble CD4 and peptides reflective of CCR5 or CXCR4 gpl20 binding sites bound to gplβO. Figure 4 shows BlAcore measurements of binding interactions between soluble gpl20 of HIV isolate DH12 and soluble CD4. Figure 5 shows binding interactions between HIV 89.6, JRFL, and DH12 soluble gpl20 proteins and soluble CD4. Figure 6 shows kinetic and binding affinities of the interactions between gpl20 and CD4. Figure 7 shows binding of soluble CD4 to gpl20- expressing membranes from the CHO-wt (HIV-IIIB gpl60- expressing) cells. Figure 8 shows changes in gpl60 and gpl40 associated with a structure of gplβO that corresponds with the ability to induce cell fusion. Figure 9 shows "freezing" of fusogenic epitopes upon addition of DP-178 or T649 peptides that are parts of the coiled coil region and that, when added to CD4-triggered envelope, result in prevention of fusion. Figures 10A-10D show binding of CD4 and CCR5 N- terminal peptide to HIV 89.6 gpl40 oligomers . Fig. 10A. Overlay of the binding curves of interactions between immobilized CD4 and HIV envelope proteins (89.6 gpl20 and gpl40). Data show that sCD4 bound to cleaved HIV 89.6 gpl40 (cl) and to HIV 89.6 gpl20 proteins. The negative control (negative Ctrl) was generated by injecting 89.6 gpl20 proteins over a CD8 immobilized surface. Compared to HIV JRFL and DH12 gpl20 env proteins, HIV 89.6 gpl20 env bound to CD4 with a relatively higher affinity (K^= 146nM, 96nM and 23nM for JRFL, DH12 and 89.6 env respectively). These differences in K < ~[ were predominantly due to differences in the off-rate (k d = 8.8xl0 -4 s _1 , 4.7x10 " 4 s -1 , l.lxlO -4 s -1 for JRFL, DH12 and 89.6 gpl20 envelope proteins, respectively) . Fig. 10B. Binding of uncleaved CM235 gpl40 (uncl) and IIIB-gpl60 (uncl) oligomers to immobilized CD4. Data show that whereas uncleaved IIIB-gpl60 (Fig. 10B) oligomers bound poorly to CD4, uncleaved HIV CM235 gpl40 (Fig. 10B) oligomers did bind sCD4. The negative control is the same injection of IIIB- gpl60 flowing over a surface immobilized with IIIB- gpl60 proteins. Fig. IOC. CD4-gpl40 complexes (indicated by arrow) were first formed by injecting soluble 89.6 gpl40 oligomers over a CD4-immobilized surface. Then the CCR5 N-terminal peptide (Dl) was injected to monitor its binding to CD4-gpl40 complexes. Fig. 10D. An overlay of the binding curves of CCR5 N-terminal peptide, Dl, binding to 89.6 gpl40 oligomers in the presence and absence of CD4. On a CD4-gpl40 complex, the Dl peptide binds with an apparent K d of 280nM (k a =9xl0 3 M-is -1 , k d = 2.56xl0 ~3 s ~ l) . In the absence of CD4, the Dl peptide binds constitutively to cleaved gpl40 oligomers with a similar on-rate but a faster off-rate (k d =0.01 s-- * -; K d = lμM) . The difference in the steady-state binding of CCR5-D1 peptide in the presence and absence of CD4 is a quantitative effect. To ensure that all gpl40 molecules were bound to CD4, cleaved gpl40 proteins were captured on a CD4 immobilized sensor surface (RU=530), and soluble 89.6 gpl40 proteins were directly immobilized (RU=3300) on an adjacent flow cell of the same sensor chip. Figures 11A-11D show CD4 and CCR5 extracellular domain peptides induce binding of the HR-2 peptides to HIV 89.6 gpl40. Fig. 11A. Binding of HR-2 peptide, DP178 following binding of 89.6 gpl40 oligomers to CD4 (solid line) , CD4 and CCR5-D1 peptide (broken line) , CCR5-D1 peptide (solid circle) and to gpl40 oligomers alone (broken lines) . Fig. 11B. Binding of the HR-2 peptide, T649QL to 89.6 gpl40 oligomers (broken line), CD4-gpl40 complex (open circle) and to CD4-gpl40-Dl complex (solid line) . 89.6 gpl40 proteins and CCR5-D1 peptide were sequentially injected over a sCD4 immobilized surface (see Fig. IOC) . Fig. llC. Binding of HR-2 peptides, DP178 and a control scrambled DP178 peptides to CD4-89.6 gpl40 complexes . Fig. 11D. Kinetics data for the binding of HR-2 peptides, DP178 and T649QL to 89.6 gpl40 after induction with CD4 and the CCR5-D1 peptide. Rm refers to the RU bound at steady-state during the injection of the same cone of HR-2 peptides (5mM) over the indicated gpl40 complexes. nm= rate constants could not be measured due to extremely low affinity binding of HR-2 peptides to gpl40 proteins. Figure 12 shows immunoprecipitation by HR-2 peptide and western blot analysis of 89.6 gpl40 envelope proteins. Biotinylated HR-2 peptide, DP178 constitutively immunoprecipitated both 'cleaved gp41 and uncleaved gpl40 proteins. The level of immunoprecipitated gpl40 and gp41 was augmented by sCD4. HIV 89.6 gpl40 proteins were incubated with 2.5 μg of biotinylated DP178 in the presence (Lanes 1 and 5) or absence (Lanes 3 and 7) of sCD4 (2 μg) . As controls, HIV 89.6 gpl40 proteins were also incubated with 2.5 μg of biotinylated scrambled DP178 peptide in the presence (Lanes 2 and 6) or absence (Lanes 4 and the gpl40 preparation immunoblotted with mab 7B2 (anti-gp41) , while Lane 10 shows gpl20 within the gpl40 preparation reactive with mab T8 (anti-gpl20) . . Figure 13 shows the induced binding of HR-2 peptides to soluble HIV 89.6 gpl40 envelope. Figures 14A-14F show induction of HR-2 peptide binding to 89.6 gpl40 by soluble CD4. Fig. 14A. Capture of soluble 89.6 gpl40 over a CD4 (solid lines) and T8 (broken lines) immobilized surface. Roughly 3000 to 5000 RU of sCD4 and T8 mab were immobilized on a CM5 sensor chip. Soluble 89.6 gpl40 proteins were then captured to the same level on both surfaces and are labeled CD4-gpl40 and T8-gpl40 respectively. Figs. 14B and 14C. Binding of the 19b (Fig. 14B) and 2F5 (Fig. 14C) antibodies to CD4-gpl40 (solid line) and T8-gpl40 (broken line) complexes. After stabilization of gpl40 capture, either the 19b (anti- gpl20 V3) or 2F5 (anti-gp41) antibodies (300μg/ml) were injected to assess the relative amounts of gpl20 and gp41 on both surfaces. Figs. 14D-14F. Binding of HR-2 peptide, DP178 (Figs. 14D) , scrambled DP178 (Figs. 14Ξ) and T649Q26L (Figs. 14E) to CD4-gpl40 (solid line) or T8-gpl40 (broken line) surfaces. 50 μg/ml of each HR-2 peptide was injected at 30μl/min over both CD4 and T8 surfaces . Figures 15A-15E show binding interactions of HR-2 peptides with CD4-gpl40 and CD4-gpl20 complexes. Figs. 15A and 15B. Overlay of the binding curves showing the interactions between HR-2 peptides, DP178 (Fig. 15A) and T649Q26L (Fig. 15B) , and CD4-gpl20 (broken lines) and CD4-gpl40 (solid lines) . Figs. 15A and 15B show the titration of the HR-2 peptide DP178 and T649Q26L between 12.5 to lOOμg/ml over CD4-gpl40 (solid lines) and CD4-gpl20 (broken lines) surfaces. Fig. 15C. There was no binding of scrambled DP178 HR-2 peptide to either CD4-gpl40 or T8-gpl40. Fig. 15D. CD4 induced HR-2 peptide binding to gpl20 envelope proteins. There was no specific binding of HR-2 peptides to the T8-gpl20 complex, while the sCD4-gpl20 and sCD4-gpl40 surfaces did stably bind HR-2 peptides. Compared to CD4-gpl20, higher binding was observed with CD4-gpl40. Table in Fig. 15E shows the binding rate constants and dissociation constants for the HR-2 peptides and CD4-gpl20 and CD4-gpl40 complexes. Data are representative of 2 separate experiments. HR-2 peptides were injected at 30 μl/min simultaneously over a blank, sCD4 and a sCD4-gpl20 or sCD4-gpl40 surfaces. The curves presented show specific binding to CD4-gpl20 or CD4-gpl40 and were derived after subtraction of binding signals from blank and sCD4 surfaces . Figures 16A-16F show constitutive binding of HR-2 peptides to immobilized gp41 and CD4 induced binding to gpl40. Fig. 16A and 16B. Binding of DP178 (12.5 to lOOμg/ml) to immobilized ADA gp41 and CD4-gpl40 (Fig. 16B) surfaces. Figs. 16C and 16D. Binding of scrambled DP178 (12.5 to 100 μg/ml, Fig. 16D) to immobilized ADA gp41 and the binding of HR-2 peptide, DP178 (12.5 to 50 μg/ml) to T8-gpl40 surfaces. Figs. 16E and 16F. Scatchard plots of RU vs RU/C for DP178 binding to gp41 (Fig. 16E) and to CD4-gpl40 (Fig. 16F) . Data are representative of 2 separate experiments . Figures 17A and 17B show induction of HR-2 peptide binding to gpl20-gp41 complex. Binding of HR- 2 peptide DP178 (50 μg/ml) to immobilized gp41, gp41- gpl20 and gp41-gpl20-CD4 complexes. Compared to gp41 surface, higher binding of DP178 is observed on gp41- gpl20 and gp41-gpl20-CD4 surfaces. Soluble 89.6 gpl20 (100 μg/ml) or a gpl20-CD4 mixture (gpl20 pre- incubated with 0.3 mg/ml of CD4 for 30 min) was injected at 5 μl/min for 10 min over a sensor surface immobilized with ADA gp41. At the end of the injections, wash buffer (PBS) was allowed to flow until the surface was stable with no baseline drift. Roughly 300 RU of gpl20 and 850 RU of gpl20-CD4 formed stable complexes with the immobilized gp41 surface. The gpl20-CD4 binding was subsequently reduced to about 325 RU (to be rougly equivalent to gp41-gpl20 surface) with short injections of a regeneration buffer (lOmM glycine-HCl, pH 2.0), followed by an injection of gpl20-CD4 mixture. Thus both surfaces were stable and had equivalent amount of associated gpl20 or gpl20-CD4. Figure 18. Soluble CD4 binding to HIV gpl20 non- covalently linked to gp41 results in binding of HR-2 to gpl20 and upregulation of gp41-gpl20 association. An immunogen is cross-linked CD4-gpl20-gp41 in soluble form. Figure 19. A32 binding to HIV gpl20 non- covalently linked to gp41 results in binding of HR-2 to gpl20 and upregulation of gp41-gpl20 association. An immunogen is cross-linked A32 (whole Ig) -gpl20-gp41 in soluble form or A32 (Fab or Fab2 ) -gpl20-gp41 in soluble form. Figure 20. Soluble CD4 binding to soluble gpl20 results in exposure of the CCR5 binding site, and the gp41 HR-2 binding site. Figure 21. A32 mab binding to soluble HIV gpl20 results in exposure of the CD4 binding site and the CCR5 binding site. Figure 22. Soluble CD4 binding to soluble uncleaved HIV gpl40 upregulates HR-2 binding to HR-1 in gp41, and exposes the CCR5 binding site. An immunogen is crosslinked CD4-gpl40 with or without DP178 or T649Q26L bound. Figure 23. Mab A32 binding to soluble uncleaved HIV gpl40 upregulates HR-2 binding to HR-1 in gp41, and exposes the CCR5 binding site. An immunogen is crosslinked A32 or a fragment thereof-gpl40 with or without DP178 or T649Q26L bound to gp41 or elsewhere in the complex. Figure 24. Soluble CD4 binding to HIV gpl20 non-covalently linked to gp41 results in binding of HR-2 to gpl20 and upregulation of gp41-gpl20 association. An immunogen is cross-linked CD4-gpl20- gp41 in soluble form, with HR-2 peptides bound to HR- 1. Figure 25. A32 binding to HIV gpl20 non- covalently linked to gp41 results in binding of HR-2 to gpl20 and upregulation of gp41-gpl20 association. An immunogen is cross-linked A32 (whole Ig) -gpl20-gp41 in soluble form or A32 (Fab or Fab2 ) -gpl20-gp41 in soluble form, with HR-2 peptide bound to HR-1 or elsewhere in the complex. Figure 26. Induction of HR-2 peptide binding to HIV 89.6 gpl40 by soluble CD4. Soluble 89.6 gpl40 proteins were captured to the same level on all three surfaces and are labeled CD4-gpl40, T8-gpl40 and A32- gpl40. Figure shows binding of HR-2 peptide DP178 to T8-gpl40 (circle) , CD4-gpl40 (solid line) and A32- gpl40 (broken line) complexes. 50 μg/ml of HR-2 peptide was injected at 30μl/min over A32, CD4 and T8 surfaces. Only specific binding, after bulk responses and non-specific binding of HR-2 peptides to sCD4, T8 and A32 surfaces were subtracted, are shown. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an immunogen that induces broadly reactive neutralizing antibodies that are necessary for an effective AIDS vaccine. In one embodiment, the immunogen comprises a cleaved or uncleaved gpl40 or gpl60 HIV envelope protein that has been "activated" to expose intermediate conformations of conserved neutralization epitopes that normally are only transiently or less well exposed on the surface of the HIV virion. The immunogen is a "frozen" triggered form of HIV envelope that makes available specific epitopes for presentation to B lymphocytes. The result of this epitope presentation is the production of antibodies that broadly neutralize HIV. The concept of a fusion intermediate immunogen is consistent with observations that the gp41 HR-2 region peptide, DP178, can capture an uncoiled conformation of gp41 (Furata et al, Nature Struct. Biol . 5:276 (1998)), and that formalin-fixed HIV-infected cells can generate broadly neutralizing antibodies (LaCasse et al, Science 283:357 (1997)). Recently a monoclonal antibody against the coiled-coil region bound to a conformatlonal determinant of gp41 in HR1 and HR2 regions of the coiled-coil gp41 structure, but did not neutralize HIV (Jiang et al, J. Virol. 10213 (1998)). However, this latter study proved that the coiled-coil region is available for antibody to bind if the correct antibody is generated. Conserved neutralization sites on the HIV envelope can be on two regions; they can be on gp41 and they can be on gpl20. The regions and conformations of gp41 that are exposed during gpl40 or gpl60 "triggering" ("activation") can be expected to be conserved since: i) the amino acid sequences of the coiled-coil region are conserved and ii) the function of the fusogenic envelope complex is conserved and essential for virus pathogenicity . This conservation is key to the production of broadly neutralizing anti-HIV antibodies . The immunogen of one aspect of the invention comprises HIV envelope cleaved or uncleaved gpl40 or gplδO either in soluble form or anchored, for example, in cell vesicles made from gpl40 or gplδO expressing cells, or in liposomes containing translipid bilayer HIV gpl40 or gpl60 envelope. Alternatively, triggered gpl60 in aldrithio 1-2 inactivated HIV-1 virions can be used as an immunogen. The gpl60 can also exist as a recombinant protein either as gpl60 or gpl40 (gpl40 is gpl60 with the transmembrane region and possibly other gp41 regions deleted) . Bound to gpl60 or gpl40 can be recombinant CCR5 or CXCR4 co-receptor proteins (or their extracellular domain peptide or protein fragments) or antibodies or other ligands that bind to the CXCR4 or CCR5 binding site on gpl20, and/or soluble CD4 , or antibodies or other ligands that mimic the binding actions of CD4 (Figure 1) . Alternatively, vesicles or liposomes containing CD4, CCR5 (or CXCR4) (Figure 2), or soluble CD4 and peptides reflective of CCR5 or CXCR4 gpl20 binding sites (Figure 3) . Alternatively, an optimal CCR5 peptide ligand can be a peptide from the N-terminus of CCR5 wherein specific tyrosines are sulfated (Bormier et al, Proc . Natl . Acad. Sci. USA 97:5762 (2001)). The data in Figure 13 clearly indicate that the triggered immunogen may not need to be bound to a membrane but may exist and be triggered in solution. Alternatively, soluble CD4 (sCD4) can be replaced by an envelope (gpl40 or gpl60) triggered by CD4 peptide mimetopes (Vitra et al, Proc. Natl. Acad. Sci. USA 96:1301 (1999)). Other HIV co- receptor molecules that "trigger" the gpl60 or gpl40 to undergo changes associated with a structure of gpl60 that induces cell fusion can also be used. (See also Fig. 8.) The data presented in Example 2 demonstrate that ligation of soluble HIV gpl40 primary isolate HIV 89.6 envelope with soluble CD4 (sCD4) induced conformational changes in gp41 (see Fig. 13) . In one embodiment, the invention relates to an immunogen that has the characteristics of a receptor (CD4) -ligated envelope with CCR5 binding region exposed but unlike CD4-ligated proteins that have the CD4 binding site blocked, this immunogen has the CD4 binding site exposed (open) . Moreover, this immunogen can be devoid of host CD4, which avoids the production of potentially harmful anti-CD4 antibodies upon administration to a host. (See Figures 18-25.) The immunogen can comprise gpl20 envelope ligated with a ligand that binds to a site on gpl20 recognized by an A32 monoclonal antibodies (mab) (Wyatt et al, J. Virol. 69:5723 (1995), Boots et al, AIDS Res. Hum. Retro. 13:1549 (1997), Moore et al, J. Virol. 68:8350 (1994), Sullivan et al, J. Virol. 72:4694 (1998), Fouts et al, J. Virol. 71:2779 (1997), Ye et al , J. Virol. 74:11955 (2000)). One A32 mab has been shown to mimic CD4 and when bound to gpl20, upregulates (exposes) the CCR5 binding site (Wyatt et al, J. Virol. 69:5723 (1995)). Ligation of gpl20 with such a ligand also upregulates the CD4 binding site and does not block CD4 binding to gpl20. Advantageously, such ligands also upregulate the HR-2 binding site of gp41 bound to cleaved gpl20, uncleaved gpl40 and cleaved gp41, thereby further exposing HR-2 binding sites on these proteins - each of which are potential targets for anti-HIV neutralizing antibodies. In a specific aspect of this embodiment, the immunogen comprises soluble HIV gpl20 envelope ligated with either an intact A32 mab, a Fab2 fragment of an A32 mab, or a Fab fragment of an A32 mab, with the result that the CD4 binding site, the CCR5 binding site and the HR-2 binding site on gpl20 are exposed/upregulated. The immunogen can comprise gpl20 with an A32 mab (or fragment thereof) bound or can comprise gpl20 with an A32 mab (or fragment thereof) bound and cross-linked with a cross-linker such as .3% formaldehyde or a heterobifunctional cross-linker such as DTSSP (Pierce Chemical Company) . The immunogen can also comprise uncleaved gpl40 or a mixture of uncleaved gpl40, cleaved gp41 and cleaved gpl20. An A32 mab (or fragment thereof) bound to gpl40 and/or gpl20 or to gpl20 non-covalently bound to gp41, results in upregulation (exposure) of HR-2 binding sites in gp41, gpl20 and uncleaved gpl40. Binding of an A32 mab (or fragment thereof) to gpl20 or gpl40 also results in upregulation of the CD4 binding site and the CCR5 binding site. As with gpl20 containing complexes, complexes comprising uncleaved gpl40 and an A32 mab (or fragment thereof) can be used as an immunogen uncross-linked or cross-linked with cross- linker such as .3% formaldehyde or DTSSP. In one embodiment, the invention relates to an immunogen comprising soluble uncleaved gpl40 bound and cross linked to a Fab fragment of an A32 mab, optionally bound and cross-linked to an HR-2 binding protein. The gpl20 or gpl40 HIV envelope protein triggered with a ligand that binds to the A32 mab binding site on gpl20 can be administered in combination with at least a second immunogen comprising a second envelope, triggered by a ligand that binds to a site distinct from the A32 mab binding site, such as the CCR5 binding site recognized by mab 17b. The 17b mab (Kwong et al, Nature 393:648 (1998) available from the AIDS Reference Repository, NIAID, NIH) augments sCD4 binding to gpl20. This second immunogen (which can also be used alone or in combination with triggered immunogens other than that described above) can, for example, comprise soluble HIV gpl20 envelope ligated with either the whole 17b mab, a Fab2 fragment of the 17b mab, or a Fab fragment of the 17b mab. It will be appreciated that other CCR5 ligands, including other antibodies (or fragments thereof) , that result in the CD4 binding site being exposed can be used in lieu of the 17b mab. This further immunogen can comprise gpl20 with the 17b mab, or fragment thereof, (or other CCR5 ligand as indicated above) bound or can comprise gpl20 with the 17b mab, or fragment thereof, (or other CCR5 ligand as indicated above) bound and cross-linked with an agent such as .3% formaldehyde or a heterobifunctional cross-linker, such as DTSSP (Pierce Chemical Company) . Alternatively, this further immunogen can comprise uncleaved gpl40 present alone or in a mixture of cleaved gp41 and cleaved gpl20. Mab 17b, or fragment thereof (or other CCR5 ligand as indicated above) bound to gpl40 and/or gpl20 in such a mixture results in exposure of the CD4 binding region. The 17b mab, or fragment thereof, (or other CCR5 ligand as indicated above) -gpl40 complexes can be present uncross-linked or cross-linked with an agent such as .3% formaldehyde or DTSSP. Soluble HR-2 peptides, such as T649Q26L and DP178 (see below) , can be added to the above-described complexes to stabilize epitopes on gpl20 and gp41 as well as uncleaved gpl40 molecules, and can be administered either cross-linked or uncross-linked with the complex. A series of monoclonal antibodies (mabs) have been made that neutralize many HIV primary isolates, including, in addition to the 17b mab described above, mab IgGlbl2 that binds to the CD4 binding site on gpl20(Roben et al, J. Virol. 68:482 (1994), Mo et al, J. Virol. 71:6869 (1997)), mab 2G12 that binds to a conformational determinant on gpl20 (Trkola et al, J. Virol. 70:1100 (1996)), and mab 2F5 that binds to a membrane proximal region of gp41 (Muster et al, J. Virol. 68:4031 (1994)). A mixture of triggered envelope immunogens can be used to optimize induction of antibodies that neutralize a broad spectrum of HIV primary isolates. Such immunogens, when administered to a primate, for example, either systemically or at a mucosal site, induce broadly reactive neutralizing antibodies to primary HIV isolates. As indicated above, various approaches can be used to "freeze" fusogenic epitopes in accordance with the invention. For example, "freezing" can be effected by addition of the DP-178 or T-649Q26L peptides . that represent portions of the coiled coil region, and that when added to CD4-triggered envelop, result in prevention of fusion (Rimsky et al, J. Virol. 72:986-993 (1998) (see Figures 9 and 13). HR-2 peptide bound gpl40, gp41 or gpl60 can be used as an immunogen or crosslinked by a reagent such as DTSSP or DSP (Pierce Co.), formaldehyde or other crosslinking agent that has a similar effect (see below) . "Freezing" can also be effected by the addition of 0.1% to 3% formaldehyde or paraformaldehyde, both protein cross-linking agents, to the complex, to stabilize the CD4, CCR5 or CXCR4, HR-2 peptide gpl60 complex, or to stabilize the "triggered" gp41 molecule, or both (LaCasse et al, Science 283:357-362 (1999) ) . Further, "freezing" of gp41 or gpl20 fusion intermediates can be effected by addition of heterobifunctional agents such as DSP (dithiobis [succimidylproprionate] ) (Pierce Co. Rockford, ILL., No. 22585ZZ) or the water soluble DTSSP (Pierce Co.) that use two NHS esters that are reactive with amino groups to cross link and stabilize the CD4, CCR5 or CXCR4 , HR-2 peptide gplδO complex, or to stabilize the "triggered" gp41 molecule, or both. Inherent differences exist in HIV isolates among HIV clades and among HIV isolates from patients in varying geographic locations. Triggered complexes for HIV vaccine development can be made with HIV envelopes from a variety of HIV clades and from a variety of locations. Triggered complexes comprising antibodies or fragments thereof that upregulate the CCR5 binding site, the CD4 binding site, or both, or antibodies, or fragments thereof, that are CD4 inducible can be produced by co-expressing in a dicistronic manner in a plasmid both gpl20 and, for example, the heavy and light chain of the Fab region of the antibody, in order to produce a recombinant protein that has the properties of the above described complexes. The immunogen of the invention can be formulated with a pharmaceutically acceptable carrier and/or adjuvant (such as alum) using techniques well known in the art. Suitable routes of administration of the present immunogen include systemic (e.g. intramuscular or subcutaneous) . Alternative routes can be used when an immune response is sought in a mucosal immune system (e.g., intranasal) . Certain aspects of the invention are described in greater detail in the non-limiting Example that follows . EXAMPLE 1 The feasibility of the immunogen production approach of the present invention has been shown using BiaCore 3000 technology. Figure 4 shows that CD4 , not CD8 , can be bound to gpl20. Figures 5, 6 show the differences in interaction of gpl20 with the envelop of primary isolates and lab-adapted HIV strains. Figure 7 shows that vesicles from chimeric hamster ovary cells transfected with HIV-IIIB gpl60 and that these vesicles, present on a BiaCore Ll Chip, 'show stabilized binding of soluble CD4 but not CD8. EXAMPLE 2 Experimental Details Proteins Soluble, monomeric gpl20 JRFL, gpl20 DH12 and sCD4 were produced by Progenies, and were provided by the Division of AIDS, NIAID, NIH. HIVIIIB gpl60 was obtained from Protein Sciences. Envelope proteins from HIV 89.6 (Clade B) , and HIV CM235 (Clade E) primary isolates were produced by Pat Earl, NIH, using recombinant vaccinia viruses and purified as described (Earl et al , J. Virol. 68:3015-3026 (1994), Earl et al, J. Virol. 75:645-653 (2001)). Briefly, BS-C-1 cells in 160 cm 2 flasks were infected with vBDl (HIV 89.6 gpl40) or vBD2 (gpl20) vaccinia viruses. After 2h, the cells were washed in PBS and placed in serum-free OPTI-MEM media (Gibco) for 24-26 hr. The culture medium was then harvested by centrifugation and filtration (0.2μm) and then TX-100 was added to 0.5% (final cone, v/v) . For some of the experiments, the culture medium was concentrated 15-30 fold and served as a source of multimeric gpl40 glycoproteins (a mix of cleaved and uncleaved form) . Further purification of these glycoproteins was performed using a two-step procedure. In the first step, contaminating proteins were removed and glycoproteins from the medium were bound to a lentil lectin column and eluted with methyl α-D- mannopyranoside. This preparation contained -50:50 cleaved and uncleaved gpl40 and the per-purified culture supernatant concentrate are termed "cleaved gpl40". Finally, oligomeric and di eric gpl40 were separated and purified by size exclusion chromatography. This gpl40 preparation is termed "uncleaved gpl40". The glycoprotein fractions were pooled and concentrated using micro-concentrators . Monoclonal Antibodies Human monoclonal antibody against the gpl20 V3 loop (19b) the CCR5 binding site (17b), and mab 7B2 against the immunodominant region of gp41 were the gifts of James Robinson (Tulane University, New Orleans, LA) . Mabs 2F5 , IgGlbl2 and 2G12 were obtained from the AIDS References Repository, NIAID, NIH. CCR5 and HR-2 Peptides . Synthetic peptides were synthesized (SynPep Corporation, Dublin, CA) , and purified by reverse phase HPLC. Peptides used in this study had greater than 95% purity as determined by HPLC, and confirmed to be correct by mass spectrometry. The CCR5-D1 (MDYQVSSPIYDINYYTSEPCQKINVKQIAAR) , peptide was derived from the N-terminus of human CCR5 (Bieniasz et al, EMBO Journal 16:2599-2609 (1997)). Gp41 peptides DP- 178 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF (Wild et al, Proc. Natl. Acad. Sci. USA 91:12676-12680 (1994)), T- 649 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL (Rimsky et al, J. Virol. 72:986-993 (1998)), and T649-Q26L (WMEWDREINNYTSLIHSLIEESQNQLEKNEQELLEL) (Shu et al, Biochemistry 39:1634-1642 (2000)) were derived from HIV-1 envelope gp41 from HIV 89.6 (Collmann et al, J. Virol. 66:7517-7521 (1992)). As a control for HR-2 peptide binding, a scrambled sequence DP178 peptide was made as well . Surface Plasmon Resonance Biosensor Measurements SPR biosensor measurements were determined on a BIAcore 3000 (BIAcore Inc., Uppsala, Sweden) instrument. HIV envelope proteins (gpl20, gpl40, gpl60) and sCD4 were diluted to 100-300 mg/ l in lOmM Na-Acetate buffer, pH 4.5 and directly immobilized to a CM5 sensor chip using standard amine coupling protocol for protein immobilization (Alam et al, Nature 381:616-620 (1996)). Binding of proteins and peptides was monitored in real-time at 25°C and with a continuous flow of PBS, pH 7.4 at 5-20ml/min. Analyte (proteins and peptides) were removed and the sensor surfaces were regenerated following each cycle of binding by single or duplicate 5-10 ml pulses of regeneration solution (10 mM glycine-HCl, pH 2.5 or lOmM NaOH) . All analyses were performed using the non-linear fit method of O'Shannessy et al . (O'Shannessy et al, Anal. Biochem. 205:132-136 (1992)) and the BIAevaluation 3.0 software (BIAcore Inc) . Rate and equilibrium constants were derived from curve fitting to the Langmuir equation for a simple bimolecular interaction (A + B = AB) . In preliminary SPR experiments, it was determined that HIV gpl20 envelope protein for HIV89.6 bound sCD4 most avidly with relatively little baseline drift (tj_/2 of binding, 105 min.) compared to HIV gpl20 DH12 (tχ 2 of binding, 25 min) and HIV gpl20 JRFL (t 1/ of binding, 14 min.). Thus, HIV89.6 gpl20 and gpl40 were produced for subsequent experiments . Immunoprecipi tation of HIV Envelope Proteins Followed by Western Blot Analysis . Soluble HIV 89.6 gpl40 or gpl20 proteins were incubated with or without 2μg of recombinant sCD4 , and a dose range if either biotinylated DP178 or biotinylated scrambled DP178 as a control in a total volume of 50μl PBS for 2h followed by incubation (4h) with 50μl suspension of streptavidin-agarose beads (Sigma Chemicals, St. Louis, MO) . Immune complexes were washed x3 with 500μl of PBS, resuspended in SDS-PAGE sample buffer containing 2-ME, boiled for 5 min, and loaded onto SDS-PAGE on 4-20% polyacrylamide gels. Gels were transferred to immunoblot membranes for Western blot analysis with either abs T8 (anti-gpl20 N-terminus) or 7B2 (anti-gp41 immunodominant region) . Results Binding of sCD4 to Cleaved and Uncleaved HIV Envelope. Preliminary SPR studies showed that, of HIV gpl20 envelopes JRFL, DH12 and 89.6, the HIV 89.6 gpl20 demonstrated the most stable binding to sCD4 (see Figure 10A) . Thus, preparations of HIV89.6 gpl40 envelope proteins were studied that contained either cleaved or primarily uncleaved gpl40 for binding to sCD4. Non-cleaved HIV CM235 gpl40 and, as well, cleaved HIV 89.6 gpl40, were tested for their ability to bind sCD4 covalently anchored on the chip in the SPR biosensor assay. Cleaved 89.6 gpl40 bound sCD4 well (Figure 10A) . The uncleaved baculovirus-produced HIV IIIB gplδO from Protein Sciences did not bind sCD4 (Mascola et al, J. Infect. Dis. 173:340-348 (1996)) (Figure 10B) . However, cleavage of gpl40 into gpl20 and truncated gp41 was not an absolute requirement for binding of sCD4 to envelope preparations, as the uncleaved Clade E envelope HIV CM235 gpl40 also bound sCD4 (Figure 10B) . Binding of an N- terminal CCR5 Extracellular Domain Peptide to HIV 89 . 6 gpl40 Envelope . The CCR5 binding site on HIV gpl20 is inducible by sCD4 (Kwong et al, Nature 393:648-659 (1998), Rizzuto et al, Science 280:1949-1953 (1998), Wyatt et al, Nature 393:705-710 (1998)) . It was next determined if an N-terminal CCR5 extracellular domain synthetic peptide could be made that bound to HIV 89.6 gpl40. A 30 aa peptide was produced from the N-terminus of CCR5 (termed CCR5-D1) , and tested for ability to bind to cleaved HIV 89.6 gpl40. Low levels of constitutive binding of the CCR5-D1 peptide to cleaved gpl40 were found, while sCD4 binding to cleaved gpl40 envelope induced more stable binding of CCR5-D1 binding to gpl40 (Figures 10C and 10D) . Doms et al have found that the affinity of native CCR5 to sCD4 ligated gpl20 in the context of membrane bound, envelope was 500 μM (Hoffman et al, Proc. Natl. Acad. Sci. 97:11215-11220 (2000)). The binding affinity of this CCR5-D1 N-terminal domain peptide to sCD4-ligated gpl40 was found to be ~280μM (Figure 10D) . Effect of Soluble CD4 and the CCR5-D1 Extracellular Domain Peptide on the Binding of HR-2 Peptides to Cleaved HIV 89 . 6 gpl40 Envelope Proteins . A major goal of this study was to determine if fusion- associated conformations of gp41 could be detected using SPR assays of HR-2 peptide binding. It was reasoned that if HR-2 peptides can bind gpl40, the gp41 coiled-coil structure must be uncoiled, such that endogenous HR-2 is not bound to HR-1. Three such HR-2 peptides were used in this study, DP178 (Wild et al, Proc. Natl. Acad. Sci. USA 91:12676-12680 (1994), Rimsky et al, J. Virol. 72:986-993 (1998)), T-649 (Rimsky et al, J. Virol. 72:986-993 (1998)), and T649Q26L (Shu et al, Biochemistry 39:1634-1642 (2000)). DP178 contains C-terminal amino acids of HR- 2 (Wild et al, Proc. Natl. Acad. Sci. USA 91:12676- 12680 (1994), Rimsky et al, J. Virol. 72:986-993 (1998)) while T649Q26L contains more N-terminal amino acids of HR-2 (Rimsky et al, J. Virol. 72:986-993 (1998), Shu et al, Biochemistry 39:1634-1642 (2000)). Low level binding DP178 to cleaved HIV 89.6 gpl40 was found (Figure 11A) , and DP178 control scrambled peptide did not bind at all (Figure 11C) . When binding of HR-2 peptides were determined on cleaved gpl40 ligated with sCD4 , DP178 HR-2 peptide binding was induced on cleaved gpl40 by sCD4 (Figure 11A) . Addition of the CCR5-D1 N-terminal peptide to sCD4-gpl40 complexes did not significantly change the Kd of DP178 binding to gpl40 (0.7 to l.lμM) but did slow the on rate of DP178 binding (7.9xl0 _ 3 M _1 s _1 to 3.47xl0-3 M _ 1 s _ l) indicating possibly an induction of protein conformation change (Figures 11A, 11B and Table in Figure 11) . The T649Q26L HR-2 peptide was designed to be of higher affinity for binding to HR-1 by the Q26L substitution (Shu et al, Biochemistry 39:1634-1642 (2000)), and indeed, in this study, T649Q26L also bound to ligated, cleaved CD4-gpl40 complexes. Soluble CD4 increased the maximal DP178 binding to cleaved gpl40 at equilibrium (Rm) by -10 fold (from an Rm of DP178 binding with no sCD4 of 35 RU (response units) to an Rm of 320 RU with sCD4) (Figure 11) . The kd, s _1 (off-rate) of binding for DP178 to cleaved gpl40 after sCD4 was .0056. sCD4 binding to cleaved gpl40 oligomers resulted in a t 1/2 of DP178 binding of 124 sec. The kd of binding for DP178 to sCD4 and CCR5-D1 ligated cleaved gpl40 89.6 was l.lμM. An additional control for the specificity of HR-2 peptide binding was the demonstration that the DP178 HR-2 peptide did not bind to sCD4-ligated gpl20. Abili ty of Biotinylated HR-2 Peptide to I munoprecipi tate HIV Envelope Proteins . To identify the components in gpl40 to which HR-2 peptides bind in solution, gpl40 envelope was immunoprecipitated with biotinylated DP178 HR-2 peptide, and then the proteins bound to biotinylated HR-2 were analyzed by Western blot analysis. Figure 12 shows the HIV envelope components present in cleaved HIV 89.6 gpl40. Lane 10 shows gpl20 and gpl40, immunoblotted with anti-gpl20 mab T8. Lane 9 shows uncleaved gpl40 and gp41 immunoblotted with the anti-gp41 mab, 7B2. Figure 12 also shows that biotinylated HR-2 peptide, DP178, constitutively immunoprecipitated both cleaved gp41 (~33kd) and uncleaved gpl40 in the absence of sCD4 • (lane 3) , and the level of gpl40 and gp41 immunoprecipitated by biotinylated HR-2 was enhanced by sCD4 (lane 1) . Lanes 5 and 7 show that the anti- gpl20 mab T8 recognized the gpl20 region of the gpl40 protein immunoprecipitated by biotinylated HR-2. Control immunoprecipitations with scrambled biotinylated DP178 peptide did not immunoprecipitate significant levels of HIV envelope proteins (Lanes 2,4,6 and 8 ) . CD4-Induced Binding of HR-2 Peptides to HIV 89. 6 gpl40 Envelope Proteins . A major goal of this study was to determine if fusion associated conformations of gp41 could be detected using SPR assays of HR-2 peptide binding. It was reasoned that if HR-2 peptides can bind gpl40, the gp41 coiled-coil structure must be uncoiled, such that endogenous HR-2 is not bound to HR-1. Two such HR-2 peptides were used in this study, DP178 (Wild et al, Proc. Natl. Acad. Sci. USA 91:12676-12680 (1994), Rimsky et al, J. Virol. 72:986- 993 (1998)) and T649Q26L (Rimsky et al, J. Virol. 72:986-993 (1998), (Shu et al, Biochemistry 39:1634- 1642 (2000)). DP178 contains C-terminal amino acids of HR-2 (Wild et al, Proc. Natl. Acad. Sci. USA 91:12676-12680 (1994), Rimsky et al, J. Virol. 72:986- 993 (1998)) while T649Q26L contains more N-terminal amino acids of HR-2 (Rimsky et al, J. Virol. 72:986- 993 (1998), (Shu et al, Biochemistry 39:1634-1642 (2000) ) . HIV envelope gpl20 proteins bind to sCD4 with a relatively high affinity (Myszka et al, Proc. Natl. Acad. Sci. USA 97:9026-9031 (2000), Collman et al, J. Virol. 66:7517-7521 (1992)). In preliminary studies, it was found that soluble HIV 89.6 gpl20 protein bound strongly to immobilized sCD4, with a K d 23nM and with an off-rate of 1.1 x 10 "4 s 1 . Thus, a CD4 immobilized surface allowed a very stable capture of HIV envelope, and this approach has been used to assay HR-2 peptide binding to sCD4 bound HIV 89.6 envelope proteins . To create equivalent surfaces of tethered gpl40 and gpl20 on CM5 sensor chips, sCD4 and anti-gpl20 mab T8 immobilized on sensor chips were used as capture surf ces. A blank chip served as an in-line reference surface for subtraction of non-specific binding and bulk responses. Mab T8 bound HIV 89.6 gpl20 with an affinity of 5.6 nM. Thus, both CD4 and the mab T8 provided stable surfaces for anchoring HIV envelope proteins . Since HIV 89.6 gpl40 contains both cleaved and uncleaved gpl40, it was important to show that gp41 was present in CD4-gpl40 complexes following capture of gpl40 proteins on CD4 or mab T8 surfaces. When equivalent response unit (RU) amounts of gpl40 proteins were captured on these two surfaces (Fig. 14A) , the same level of anti-gpl20 V3 mab 19b and anti-gp41 mab 2F5 binding was observed (Figs. 14B and 14C) . Mab 2F5 reactivity could either be reacting with captured cleaved gp41 or binding to gp41 in uncleaved gpl40. Nonetheless, the captured gpl40 proteins on both of these surfaces were near identical in their reactivity with anti-gpl20 and anti-gp41 abs . The ability of HR-2 peptides to bind to captured gpl40 on mab T8 or sCD4 surfaces was tested. Binding of the HR-2 peptides showed qualitative differences in binding to mab T8 and sCD4-bound gpl40. Compared to the T8-gpl40 surface (near background binding) , the DP178 HR-2 peptide bound specifically to the sCD4- gpl40 surface (Fig. 14D) . However, there was no binding of the scrambled DP178 peptide to mab T8-gpl40 or sCD4-gpl40 surfaces (Fig. 14D) . Similar to HR-2 peptide DP178 binding, HR-2 peptide T649Q26L showed no binding to the mab T8-gpl40 surface, and marked binding to the sCD4-gpl40 surface (Fig. 14F) . Taken together, these results demonstrated that sCD4 induced the binding of both HR-2 peptides, DP178 and T649Q26L, to HIV 89.6 gpl40. HR-2 peptide binding to CD4-gpl40 compared to CD4- gp!20 compl exes . Kowalski et al . have shown that mutations in gp41 HR-2 disrupt gp41-gpl20 binding, and that HR-2 contains a touch point site of gp41 non- covalent interaction with gpl20 (Alam et al, Nature 381:616-620 (1996)). Thus, it was of interest to compare HR-2 binding to sCD4-gpl40 complexes with sCD4-gpl20 complexes in SPR assays. As in experiments in Fig. 14, HIV 89.6 gpl20 or gpl40 proteins were captured in equivalent amounts on sCD4 immobilized surfaces. Interestingly, specific binding of HR-2 peptide was detected on both sCD4-gpl40 and sCD4-gpl20 surfaces (Figs. 15A and 15B) . However, there was much higher binding of both DP178 and T649Q26L HR-2 peptides to the sCD4-gpl40 surface compared to the sCD4-gpl20 surface (Figs. 15A, 15B) . To determine if the binding of HR-2 peptides to gpl20 was induced by sCD4, HR-2 binding to sCD4-gpl20 was compared with HR- 2 binding to gpl20 proteins captured on the T8 mab surface. As shown in Fig. 15C, the binding of both HR- 2 peptides DP178 and T649Q26L to gpl20 was specifically induced by sCD4 since neither HR-2 peptide bound to gpl20 on the T8 mab surface. No binding of scrambled DP178 to CD4-gpl40 or CD4-gpl20 was detected (Fig. 15D) . Finally, to assess the affinity of the binding interactions between HR-2 peptide and sCD4 triggered HIV 89.6 gpl40 and gpl20, the rate constants were measured and the dissociation constant (K d ) for the binding of both HR-2 peptides, DP178 and T649Q26L to sCD-gpl40 and sCD4-gpl20 (Figs. 15A, 15B, and 15E) . There was little difference in the kinetics of HR-2 peptides binding to sCD4-gpl40 and sCD4-gpl20, indicating that the higher level of binding of the HR- 2 peptide to CD4-gpl40 was due to induced binding to HRl-gp41 in addition to binding sites on gpl20. The binding affinity of the HR-2 peptides for gpl20 and gpl40 were between 1.2-2.5 μM. The HR-2 binding was stable with relatively slow off-rates (t i 2 values in minutes, 7.7 to 10.5 min) on both sCD4-gpl20 and sCD4- gpl40 complexes. Binding of HR-2 peptide to recombinant gp41 . To directly determine if HR-2 peptides can constitutively bind to purified gp41, recombinant ADA gp41 was immobilized to a sensor surface and the binding of HR-2 peptide, DP178, determined. The HR-2 peptide DP178 bound well to immobilized gp41 (Fig. 16A) , while no binding was observed with the scrambled DP178 peptide (Fig. 16C) . To compare the binding of DP178 HR-2 peptide to recombinant gp41 versus HIV 89.6 gpl40-sCD4 complex, the equilibrium binding contants (Keq) of HR-2 binding to both were measured. While the Keq of DP178 binding to recombinant gp41 was weak at 26.7 μM (Fig. 16E) , the Keq of DP178 binding to sCD4-gpl40 was 10 fold stronger at 1.7 μM (Fig. 16F) . Complexes of gpl20-gp41 formed on a sensor surface can be induced by sCD4 to upregulate HR-2 peptide binding. In the preparation of HIV 89.6 gpl40 envelope, there is uncleaved gpl40, and cleaved gpl40 components of gpl20 and gp41. Thus, it is possible that HR-2 peptide could be induced to bind uncleaved gpl40 and/or could be induced to bind to cleaved gpl20 and gp41. To directly determine if binding of sCD4 to gpl20 that is non-covenlently bound to gp41 can upregulate HR-2 peptide binding to the sCD4-gpl20-gp41 complex, recombinant ADA gp41 was immobilized on a sensor chip, and HIV 89.6 gpl20 or a gpl20 sCD4 mixture was flowed over it. It was found that gpl20 bound stably to gp41 (Fig. 17) . When HR-2 peptide DP178 was flowed over the gp41-gpl20-sCD4 complex, binding of HR-2 was upregulated compared to HR-2 binding to gp41 or to the gp41-gpl20 complex (Fig. 17) . Thus, sCD4 ligation of gpl20 non- covalently bound to gp41 can upregulate either gp41 or gpl20, or both, to bind to HR-2. Neutralizing Epitopes on HIV 89 . 6 gpl40 Before and After Ligation wi th sCD4 . The 2F5 (anti-gp41, ELDKWAS) (Muster et al, J. Virol. 67:6642-6647 (1993)), mab neutralizes HIV primary isolates. Prior to ligation of cleaved 89.6 gpl40 with sCD4, it was found that the 2F5 gp41 epitope was exposed. Following sCD4 ligation, the 17b CCR5 binding site epitope (2-4) was upregulated and the 2F5 epitope continued to be expressed. EXAMPLE 3 Experimental Details Proteins . Soluble CD4 was produced by Progenies, Tarrytown, NY and was provided by the Division of AIDS, NIAID, NIH. Soluble envelope gpl20 (VBD-2) and gpl40 (VBD-1) proteins from HIV 89.6 primary isolate were produced using recombinant vaccinia viruses and purified as described (Earl et al, J. Virol. 68:3015- 3026 (1994), Earl et al, J. Virol. 75:645-653 (2001)). Briefly, BS-C-1 cells in 160 cm 2 flasks were infected with vBDl (HIV 89.6 gpl40) or vBD2 (gpl20) viruses. After 2h, the cells were washed in PBS and placed in serum-free OPTI-MEM media (Gibco) for 24 -26 hr . The culture medium was then harvested by centrifugation and filtration (0.2μm) and Tritox-X 100 added to 0.5%. For some experiments, culture medium was concentrated 15-30 fold and served as a source of gpl40 glycoproteins (a mix of cleaved and uncleaved forms) . Lentil lectin column purified gpl40 contained -50:50 cleaved and uncleaved gpl40. Recombinant HIV ADA gp41 protein was obtained from Immunodiagnostics Inc . (Woburn, MA) . HIV-1 BAL gpl20 was produced by ABL and provided by the Division of AIDS, NIAID, NIH. Monoclonal Antibodies . Mab A32 was obtained from James Robinson (Tulane University, New Orleans, LA) (Boots et al, AIDS Res. Hum. Res. 13:1549 (1997)). < A32 mab was affinity purified from serum-free media using a Staph Protein-G column. HR-2 Peptides . Synthetic peptides were synthesized (SynPep, Inc., Dublin, CA) , and purified by reverse phase HPLC. Peptides used in this study had greater than 95% purity as determined by HPLC, and confirmed to be correct by mass spectro etry . gp41 peptides DP178, YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF (Wild et al, Proc. Natl. Acad. Sci. USA 19:12676-12680 (1994)), and T649-Q26L, WMEWDREINNYTSLIHSLIEESQNQLEKNEQΞLLEL (Rimsky et al, J. Virol. 72:986-993 (1998), Shu et al, Biochemistry 39:1634-1642 (2000)) were derived from HIV-1 envelope gp41 from HIV 89.6 (Collman et al, J. Virol. 66:7517-7521 (1992)). As a control for HR-2 peptide binding, a scrambled sequence DP178 peptide was made. For immunoprecipitations and select SPR experiments, biotinylated DP178 and DP178 scrambled peptides were synthesized (SynPep, Inc.). Surface Plasmon Resonance Biosensor Measurements . SPR biosensor measurements were determined on a BIAcore 3000 (BIAcore Inc., Uppsala, Sweden) instrument. Anti-gpl20 mab (T8) or sCD4 (100-300 μg/ml) in lOmM Na- Acetate buffer, pH 4.5 were directly immobilized to a CM5 sensor chip using a standard arαine coupling protocol for protein immobilization (Alam et al, Nature -381:616-620 (1996)). A blank in-line reference surface (activated and de-activated for a ine coupling) was used to subtract non-specific or bulk responses. Binding of proteins and peptides (biotinylated or free DP178, T649Q26L, DP178- scrambled) was monitored in real-time at 25°C with a continuous flow of PBS (150 mM NaCl, 0.005% surfactant p20) , pH 7.4 at 10-30μl/min. Analyte (proteins and peptides) were removed and the sensor surfaces were regenerated following each cycle of binding by single or duplicate 5-10 μl pulses of regeneration solution (10 mM glycine-HCl, pH 2.5 or lOmM NaOH) . All analyses were performed using the non-linear fit method of O'Shannessy et al . (O'Shannessy et al, Anal. Biochem. 205:132-136 (1992)) and the BIAevaluation 3.0 software (BIAcore Inc) . Rate and equilibrium constants were derived from curve fitting to the Langmuir equation for a simple bimolecular interaction (A + B = AB) . RESULTS CD4-induced binding of HR-2 Peptides to HIV 89 . 6 gpl40 Envelope Proteins . A major goal of this study was to determine if fusion-associated conformations of gp41 could be . detected using SPR assays of HR-2 peptide binding. It was reasoned that if HR-2 peptides can bind gpl40, the gp41 coiled-coil structure must be uncoiled, such that endogenous HR-2 is not bound to HR-1. Two such HR-2 peptides were used in this study, DP178 (Wild et al, Proc. Natl. Acad. Sci. USA 19:12676-12680 (1994), Rimsky et al, J. Virol. 72:986- 993 (1998)) and T649Q26L (Rimsky et al, J. Virol. 72:986-993 (1998), Shu et al, Biochemistry 39:1634- 1642 (2000) ) . DP178 contains C-terminal amino acids of HR-2 (Wild et al, Proc. Natl. Acad. Sci. USA 19:12676-12680 (1994), (Rimsky et al, J. Virol. 72:986-993 (1998)) while T649Q26L contains more N- terminal amino acids of HR-2 (Rimsky et al, J. Virol. 72:986-993 (1998), Shu et al, Biochemistry 39:1634- 1642 (2000) ) . HIV envelope gpl20 proteins bind to sCD4 with a relatively high affinity (Myszka et al, Proc. Natl. Acad. Sci. 97:9026-9031 (2000), Collman et al, J. Virol. 66:7517-7521 (1992)). In preliminary studies, it was found that soluble HIV 89.6 gpl20 protein bound strongly to immobilized sCD4, with a K d 23nM and with an off-rate of 1.1 x 10 4 s 1 . Thus, a CD4 immobilized surface allowed a very stable capture of HIV envelope, and this approach has been used to assay HR-2 peptide binding to sCD4 bound HIV 89.6 envelope proteins. To create equivalent surfaces of tethered gpl40 and gpl20 on CM5 sensor chips, sCD4 and anti-gpl20 mab T8 immobilized on sensor chips were used as capture surfaces. A blank chip served as an in-line reference surface for subtraction of non-specific binding and bulk responses. Mab T8 bound HIV 89.6 gpl20 with an affinity of 5.6 nM. Thus, both CD4 and the mab T8 provided stable surfaces for anchoring HIV envelope proteins . Since HIV 89.6 gpl40 contains both cleaved and uncleaved gpl40, it was important to show that gp41 was present in CD4-gpl40 complexes following capture of gpl40 proteins on CD4 or mab T8 surfaces. When equivalent response unit (RU) amounts of gpl40 proteins were captured on these two surfaces, the same level of anti-gpl20 V3 mab 19b and anti-gp41 mab 2F5 binding was observed. Mab 2F5 reactivity could either be reacting with captured cleaved gp41 or binding to gp41 in uncleaved gpl40. Nonetheless, the captured gpl40 proteins on both of these surfaces were near identical in their reactivity with anti-gpl20 and anti-gp41 mabs . The ability of HR-2 peptides to bind to captured gpl40 on mab T8 or sCD4 surfaces was next tested. Binding of the HR-2 peptides showed qualitative differences in binding to mab T8 and sCD4-bound gpl40. Compared to the T8-gpl40 surface (near background binding) , the DP178 HR-2 peptide bound specifically to the sCD4-gpl40 surface. However, there was no binding of the scrambled DP178 peptide to mab T8-gpl40 or sCD4-gpl40 surfaces. Similar to HR-2 peptide DP178 binding, HR-2 peptide T649Q26L showed no binding to the mab T8-gpl40 surface, and marked binding to the sCD4-gpl40 surface. Taken together, these results demonstrated that sCD4 induced the binding of both HR- 2 peptides, DP178 and T649Q26L, to HIV 89.6 gpl40. The A32 mab has been reported to reproduce the effect of sCD4 in triggering HIV envelope to upregulated the availability of CCR5 binding site '(Wyatt et al, J. Virol 69:5723 (1995)). Thus, an A32 mab surface was used to determine if A32 mab could mimic sCD4 to upregulate HR-2 binding to captured gpl40. Similar to sCD4 , HR-2 peptide binding was markedly upregulated when gpl40 (a mixture of uncleaved gpl40, cleaved gpl20 and cleaved g41) was captured on the A32 mab surface compared to gpl40 captured on the mab T8 surface (Fig. 26) . Similar results were obtained using A32 mab and gpl20. All documents cited above are hereby incorporated in their entirety by reference. One skilled in the art will appreciate from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.

Claims: WHAT IS CLAIMED IS: 1. An isolated immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on said protein. 2. The immunogen according to claim 1 when said HIV protein is gpl20, uncleaved gpl40 or gpl20 noncovalently bound to gp41. 3. The immunogen according to claim 1 wherein said ligand is an antibody, or Fab 2 or Fab fragment thereof . 4. The immunogen according to claim 2 wherein said ligand binds to a CCR5 binding site on gpl20 and upregulates a CD4 binding site on gpl20. 5. The immunogen according to claim 4 wherein said ligand is an antibody, or Fab or Fab fragment thereof . 6. The immunogen according to claim 4 wherein said ligand is monoclonal antibody (mab) 17b, or Fab or Fab fragment thereof, or mimic thereof. 7. The immunogen according to claim 1 wherein said ligand upregulates a CCR5 and a CD4 binding site on gpl20. 8. The immunogen according to claim 7 wherein said ligand is an antibody, or Fab or Fab fragment thereof . 9. The immunogen according to claim 7 wherein said ligand binds to a site on gpl20 to which mab A32 binds . 10. The immunogen according to claim 9 wherein said ligand is mab A32, or Fab 2 or Fab fragment thereof, or mimic thereof. 11. The immunogen according to claim 1 wherein said protein and said ligand are crosslinked. 12. The immunogen according to claim 1 wherein said protein is in soluble form. 13. The immunogen according to claim 1 wherein said protein is associated with a cell vesicle or liposome. 14. The immunogen according to claim 1 wherein said protein is gpl20 noncovalently bound to gp41. 15. The immunogen according to claim 14 wherein gpl20, gp41 and said ligand are crosslinked. 16. The immunogen according to claim 14 wherein said immunogen further comprises an HR-2 peptide bound to said protein. 17. The immunogen according to claim 16 wherein gpl20, gp41, said ligand and said HR-2 peptide are crosslinked. 18. A composition comprising at least one immunogen according to claim 1 and a carrier. 19. A method of inducing the production of neutralizing antibodies to HIV in a mammal comprising administering to said mammal an amount of said immunogen according to claim 1 sufficient to effect said induction. 20. A method of screening a compound for its ability to upregulate the CD4 binding site on gpl20 comprising contacting said compound with gpl20 and mab 17b, or Fab 2 or Fab fragment thereof, or mimic thereof, and determining whether said compound competes with mab 17b, or fragment or mimetic thereof, for binding to the CCR5 binding site on said gpl20, wherein a compound that competes with mab 17b, or fragment or mimetic thereof, is a compound that potentially upregulates the CD4 binding site on gpl20. 21. The method according to claim 20 wherein mab 17b, or fragment or mimetic thereof, bears a detectable label . 22. The method according to claim 20 wherein gpl20 is bound to a solid support. 23. The method according to claim 22 wherein said solid support is BIACORE chip. 24. A method of screening a compound for its ability to upregulate the CD4 and CCR5 binding sites on gpl20 comprising contacting said compound with gρl20 and mab A32, or Fab 2 or Fab fragment thereof, or mimic thereof, and determining whether said compound competes with mab A32, or fragment or mimetic thereof, for binding to gpl20, wherein a compound that competes with mab A32, or fragment or mimetic thereof is a compound that potentially upregulates the CD4 and CCR5 binding sites on gpl20. 25. The method according to claim 24 wherein mab A32, or fragment or mimetic thereof, bears a detectable label. 26. The method according to claim 24 wherein gpl20 is bound to a solid support. 27. The method according to claim 26 wherein said solid support is BIACORE chip.

Inventors: ALAM MUNIR, HAYNES BARTON F, LIAO HUA-XIN, PATEL DHAVALKUMAR D, ALAM, MUNIR, HAYNES, BARTON, F., LIAO, HUA-XIN, PATEL, DHAVALKUMAR, D.
Applicants: UNIV DUKE, DUKE UNIVERSITY
Application year: 2001
Main classification: A61K
IPC codes: A61K39, A61K47, C07K14, C07K16